IASO-782 in Autoimmune Hematological Diseases

Recruiting Phase 1 Interventional Study
Autoimmune Thrombocytopenia Warm Autoimmune Haemolytic Anaemia
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
16 (estimated)
Sponsor
Shanghai IASO Biotechnology Co., Ltd · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of autoimmune haematological diseases (ITP and wAIHA).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age 18-65 years 2. Clinically confirmed diagnosis of autoimmune thrombocytopenia (ITP) or warm autoimmune haemolytic anaemia (wAIHA) 3. Failure or relapse after at least 1 treatment for the study disease 4. Stable dose of immunosuppressants for 4 weeks before screening 5. Org…
Contacts

Changpu Cao

+86-13584069411

changpu.cao@iasobio.com

CONTACT